Cevostamab
- Generic Name
- Cevostamab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2249888-53-5
- Unique Ingredient Identifier
- P86BHN01VE
- Associated Conditions
- -
- Associated Therapies
- -
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Phase 1
Recruiting
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05927571
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺The Alfred Hospital, Prahan, Victoria, Australia
🇮🇱Rambam Health Care Campus, Haifa, Israel
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
Phase 1
Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05646836
- Locations
- 🇬🇷
University of Athens, Hematological Clinic,, Athens, Greece
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath